Jacobio Pharma (HKG: 1167), a China-based pharmaceutical company, has announced that it has received approval from the Center for Drug Evaluation (CDE) in China to initiate a regulatory Phase III clinical study. The study will assess the combination of its KRAS G12C inhibitor glecirasib with pipeline SHP2 inhibitor JAB-3312 for the first-line treatment of non-small cell lung cancer (NSCLC) patients with a KRAS G12C mutation. The control group will receive the combination of an anti-PD-1 antibody with chemotherapy, which represents the current standard therapy for first-line NSCLC.
The oral combination of JAB-3312 and glecirasib is noted as the world’s first to reach the Phase III regulatory stage for first-line NSCLC. Glecirasib, developed in-house by Jacobio, is the subject of numerous studies in China, the United States, and Europe for NSCLC, colorectal cancer, and pancreatic cancer. JAB-3312, on the other hand, is also undergoing multiple clinical trials across China, the US, and Europe.- Flcube.com
